396076-65-6

Basic information

• Product Name: (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester
• Synonyms: (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester
• CAS NO: 396076-65-6
• Molecular Weight: 248.051
• Mol File: 396076-65-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester(396076-65-6)
• EPA Substance Registry System: (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester(396076-65-6)

Safety Data

• Hazardous Substances Data: 396076-65-6(Hazardous Substances Data)

Upstream product

• 1493-13-6 trifluorormethanesulfonic acid 
• 72755-13-6 (3-fluoro-phenyl)-carbamic acid methyl ester 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 79-22-1 methyl chloroformate 

Downstream Products

• 856677-05-9 (5S)-N-[[3-(3-fluoro-4-bromophenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide 
• 504437-66-5 (S)‐N‐((3‐(3‐fluoro‐4‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)phenyl)‐2‐oxooxazolidin‐5‐yl)methyl)acetamide 
• 1445866-03-4 methyl N-[4-(2-bromoacetyl)-3-fluorophenyl]carbamate 
• 439949-18-5 (4-Bromo-3-fluoro-2-iodo-phenyl)-carbamic acid methyl ester 

Relevant articles and documents

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

Process for the preparation of an indole derivative

A process for the preparation of indole derivatives of formula (I): which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.